These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20005515)

  • 21. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
    Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid in vivo transport and catabolism of human apolipoprotein A-IV-1 and slower catabolism of the apoA-IV-2 isoprotein.
    Rader DJ; Schäfer J; Lohse P; Verges B; Kindt M; Zech LA; Steinmetz A; Brewer HB
    J Clin Invest; 1993 Aug; 92(2):1009-17. PubMed ID: 8349786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism.
    Shepherd J; Packard CJ; Patsch JR; Gotto AM; Taunton OD
    J Clin Invest; 1979 May; 63(5):858-67. PubMed ID: 221531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
    Chan DC; Barrett HP; Watts GF
    Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibric acids: effects on lipids and lipoprotein metabolism.
    Grundy SM; Vega GL
    Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mechanisms of actions of statins and fibrates].
    Duriez P
    Therapie; 2003; 58(1):5-14. PubMed ID: 12822195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives.
    Ginsberg HN
    Am J Med; 1987 Nov; 83(5B):66-70. PubMed ID: 3318456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.
    Colin S; Briand O; Touche V; Wouters K; Baron M; Pattou F; Hanf R; Tailleux A; Chinetti G; Staels B; Lestavel S
    Eur Heart J; 2013 Aug; 34(32):2566-74. PubMed ID: 22843443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.
    Samuelsson O; Attman PO; Gause-Nilsson I; Svensson MK; Alaupovic P
    PPAR Res; 2013; 2013():391628. PubMed ID: 23606826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large.
    Onat A; Can G; Yüksel H
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):368-85. PubMed ID: 22951857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PPAR-α agonists are still on the rise: an update on clinical and experimental findings.
    Ferri N; Corsini A; Sirtori C; Ruscica M
    Expert Opin Investig Drugs; 2017 May; 26(5):593-602. PubMed ID: 28343425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anti-cholesterol agents, new therapeutic approaches].
    Fruchart JC; Duriez P
    Ann Pharm Fr; 2004 Jan; 62(1):3-18. PubMed ID: 14747768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study.
    Vergès B; Rader D; Schaefer J; Zech L; Kindt M; Fairwell T; Gambert P; Brewer HB
    J Lipid Res; 1994 Dec; 35(12):2280-91. PubMed ID: 7897325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies.
    Chan DC; Barrett PH; Watts GF
    Clin Biochem Rev; 2004 Feb; 25(1):31-48. PubMed ID: 18516204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.
    Liu ZM; Hu M; Chan P; Tomlinson B
    Expert Opin Investig Drugs; 2015 May; 24(5):611-21. PubMed ID: 25604802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein.
    Blanco-Vaca F; Escolà-Gil JC; Martín-Campos JM; Julve J
    J Lipid Res; 2001 Nov; 42(11):1727-39. PubMed ID: 11714842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.
    Prieur X; Lesnik P; Moreau M; Rodríguez JC; Doucet C; Chapman MJ; Huby T
    Biochim Biophys Acta; 2009 Aug; 1791(8):764-71. PubMed ID: 19362162
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.